Quick Answer
- • Nausea, diarrhea, vomiting, constipation
- • Abdominal pain, dyspepsia, burping, reflux
- • Injection site reactions, fatigue
- • Hypersensitivity reactions, hair loss
- • Thyroid C-cell tumors (boxed warning, rats)
- • Acute pancreatitis, acute gallbladder disease
- • Kidney injury from dehydration
- • Hypoglycemia with insulin or a sulfonylurea
The Bottom Line
- • GI symptoms, concentrated during dose escalation
- • Symptoms that decrease over time per the label
- • A four-week step built into every dose increase
- • Severe abdominal pain radiating to the back
- • Persistent vomiting or diarrhea (dehydration)
- • A neck lump, hoarseness, trouble swallowing
What We'll Cover
- 1. What are the side effects of tirzepatide?
- 2. The most common tirzepatide side effects, by dose
- 3. Mounjaro side effects in the diabetes trials
- 4. The boxed warning: thyroid C-cell tumors
- 5. Serious tirzepatide side effects the label warns about
- 6. Why titration reduces GI side effects
- 7. When the label says to seek medical care
- 8. Mounjaro vs Zepbound: same molecule, different label
- 9. Compounded tirzepatide has no FDA label
- 10. How to bring side effects to your prescriber
Tirzepatide is the active ingredient in two FDA-approved medicines from Eli Lilly: Mounjaro, approved to improve glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes, and Zepbound, approved for chronic weight management in adults with obesity or overweight with a weight-related condition, and for moderate to severe obstructive sleep apnea in adults with obesity. Both carry the same molecule and, unsurprisingly, the same safety architecture. Everything below is what those two labels actually report, with the numbers copied rather than rounded into vibes.
What Are the Side Effects of Tirzepatide?
The FDA label organizes side effects into three tiers, and it is worth understanding the difference before reading a single percentage.
- The boxed warning sits at the top of the label. It is the strongest warning the FDA applies, and for tirzepatide it concerns thyroid C-cell tumors observed in rats.
- Warnings and precautions are the serious but less-common risks a prescriber monitors for: pancreatitis, gallbladder disease, kidney injury, hypoglycemia, hypersensitivity, diabetic retinopathy complications, and pulmonary aspiration during anesthesia.
- Adverse reactions are the common, mostly tolerable symptoms measured in the clinical trials, reported with per-dose percentages against placebo.
The ZEPBOUND label summarizes the common tier this way: the most common adverse reactions reported in ≥5% of patients are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss, and gastroesophageal reflux disease. The MOUNJARO label lists a shorter set for its diabetes population: nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain.
The one-sentence version: tirzepatide side effects are gastrointestinal first, dose-escalation-weighted, and mostly reported as decreasing over time, sitting on top of a small set of serious risks that the label tells prescribers to actively watch for.
The Most Common Tirzepatide Side Effects, by Dose
The table below is Table 1 from the ZEPBOUND prescribing information: adverse reactions occurring in at least 2% of patients and more often than placebo, in the pooled weight-reduction trials (Study 1 and Study 2) that treated 2,519 adults for up to 72 weeks. These are trial rates, not predictions about any individual person.
| Adverse reaction | Placebo (N=958) | 5 mg (N=630) | 10 mg (N=948) | 15 mg (N=941) |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Constipation | 5% | 17% | 14% | 11% |
| Vomiting | 2% | 8% | 11% | 13% |
| Abdominal pain | 5% | 9% | 9% | 10% |
| Dyspepsia (indigestion) | 4% | 9% | 9% | 10% |
| Injection site reactions | 2% | 6% | 8% | 8% |
| Fatigue | 3% | 5% | 6% | 7% |
| Hypersensitivity reactions | 3% | 5% | 5% | 5% |
| Eructation (burping) | 1% | 4% | 5% | 5% |
| Hair loss | 1% | 5% | 4% | 5% |
| Gastroesophageal reflux disease | 2% | 4% | 4% | 5% |
| Dizziness | 2% | 4% | 5% | 4% |
| Flatulence | 2% | 3% | 3% | 4% |
| Abdominal distension | 2% | 3% | 3% | 4% |
| Hypotension (low blood pressure) | 0% | 1% | 1% | 2% |
Four things stand out when you read the column headers instead of the headline.
- Placebo is not zero. 8% of placebo patients reported nausea and 8% reported diarrhea. Part of what people attribute to the drug happens in trials without the drug.
- Constipation runs the other way. It is the one common reaction that was higher at 5 mg (17%) than at 15 mg (11%) in this pool.
- Any GI reaction was 56% at every maintenance dose (5 mg, 10 mg, 15 mg) versus 30% on placebo. The overall rate did not climb with dose.
- Severity did climb with dose. Severe GI reactions were 1.7% at 5 mg, 2.5% at 10 mg, and 3.1% at 15 mg, versus 1% on placebo.
The label also records how many people left the trials. Across Studies 1 and 2, 4.8%, 6.3%, and 6.7% of patients on 5 mg, 10 mg, and 15 mg permanently discontinued because of adverse reactions, versus 3.4% on placebo, and the label notes the majority did so during the first few months, driven by GI symptoms. Discontinuation specifically for GI reasons was 1.9%, 3.3%, and 4.3% versus 0.5% on placebo.
Hair loss is in the label, and it is asymmetric
The ZEPBOUND label reports hair loss in 7.1% of female and 0.5% of male treated patients (placebo: 1.3% female, 0% male), and states these events were associated with weight reduction. No treated patient discontinued because of it. If you are tracking body composition alongside a GLP-1, our guide on GLP-1 and muscle loss covers the lean-mass side of rapid weight reduction.
Mounjaro Side Effects in the Diabetes Trials
Same molecule, different population, different numbers. The table below is Table 1 from the MOUNJARO prescribing information, drawn from two placebo-controlled type 2 diabetes trials (SURPASS-1 monotherapy and SURPASS-5 with basal insulin), covering 718 patients with a mean exposure of 36.6 weeks. Only reactions reported in at least 5% of Mounjaro-treated patients appear.
| Adverse reaction | Placebo (N=235) | 5 mg (N=237) | 10 mg (N=240) | 15 mg (N=241) |
|---|---|---|---|---|
| Nausea | 4% | 12% | 15% | 18% |
| Diarrhea | 9% | 12% | 13% | 17% |
| Decreased appetite | 1% | 5% | 10% | 11% |
| Vomiting | 2% | 5% | 5% | 9% |
| Constipation | 1% | 6% | 6% | 7% |
| Dyspepsia | 3% | 8% | 8% | 5% |
| Abdominal pain | 4% | 6% | 5% | 5% |
The Mounjaro rates are consistently lower than the Zepbound rates. Do not read that as Mounjaro being a gentler drug. The label itself says adverse reaction rates from different trials cannot be directly compared, and these are different populations, different trial designs, and different durations. In the Mounjaro pool, any GI reaction rose from 37.1% at 5 mg to 39.6% at 10 mg to 43.6% at 15 mg, versus 20.4% on placebo, and discontinuation for GI reasons was 3.0%, 5.4%, and 6.6% versus 0.4%.
If you are weighing tirzepatide against semaglutide rather than against nothing, the side-effect profiles rhyme but are not identical. See our companion pages on Ozempic side effects and semaglutide vs tirzepatide.
The Boxed Warning: Thyroid C-Cell Tumors
Both tirzepatide labels open with the same boxed warning. Quoting the ZEPBOUND label directly: "In rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether ZEPBOUND causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined."
Read that carefully, because both halves matter. The rodent finding is real, dose-related, and duration-related. The human relevance is undetermined. The label does not say tirzepatide causes thyroid cancer in people, and it does not say it is safe. It leaves the question open and then acts conservatively.
The contraindication the boxed warning creates
Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It is also contraindicated in patients with known serious hypersensitivity to tirzepatide or any excipient. These are not cautions. They are the label saying do not use this drug in these people.
The label also instructs prescribers to counsel patients on the symptoms of thyroid tumors: a mass in the neck, difficulty swallowing (dysphagia), shortness of breath (dyspnea), and persistent hoarseness. And it makes a point that gets lost in consumer coverage: routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection here, because calcitonin has low test specificity and thyroid disease has a high background incidence. Routine screening can generate unnecessary procedures. That is a label instruction, not an opinion, and it is worth raising if a clinic sells you a monitoring add-on.
Serious Tirzepatide Side Effects the Label Warns About
Below the boxed warning sits Section 5, Warnings and Precautions. These are the events a prescriber is supposed to actively monitor for. Where the label reports a rate from the pooled Zepbound weight-reduction trials, it is included.
| Labeled warning | What the label reports | What the label instructs |
|---|---|---|
| Severe GI adverse reactions | Severe events in 1.7% / 2.5% / 3.1% (5 / 10 / 15 mg) vs 1% placebo | Not recommended in patients with severe gastroparesis |
| Acute pancreatitis | Adjudication-confirmed in 0.2% on Zepbound vs 0.2% placebo (Studies 1 and 2) | Discontinue if pancreatitis is suspected; watch for severe abdominal pain radiating to the back |
| Acute gallbladder disease | Cholelithiasis 1.1% vs 1%; cholecystitis 0.7% vs 0.2%; cholecystectomy 0.2% vs 0% | Gallbladder studies and clinical follow-up if cholecystitis is suspected |
| Acute kidney injury from volume depletion | Reported in 0.5% on Zepbound vs 0.2% placebo; postmarketing cases have required hemodialysis | Monitor renal function in patients reporting reactions that could cause dehydration, especially during initiation and escalation |
| Hypoglycemia with insulin or a secretagogue | Plasma glucose <54 mg/dL in 4.2% vs 1.3% placebo in the type 2 diabetes trial; 10.3% when combined with a sulfonylurea vs 2.1% without | Reducing the insulin or sulfonylurea dose may be necessary; educate all patients on hypoglycemia signs |
| Hypersensitivity reactions | Immediate reactions in 2.1% vs 0.4% placebo; severe reactions in 0.1% vs 0%; anaphylaxis and angioedema reported postmarketing | Discontinue and seek medical attention promptly if suspected |
| Diabetic retinopathy complications | Rapid glucose improvement has been associated with temporary worsening; tirzepatide has not been studied in several advanced retinopathy states | Monitor patients with a history of diabetic retinopathy for progression |
| Pulmonary aspiration under anesthesia | Rare postmarketing reports of residual gastric contents despite reported fasting adherence | Instruct patients to tell providers before any planned surgery or procedure |
Two of these deserve a second look. The retinopathy line is a caveat, not a measured risk: the label says tirzepatide has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. The absence of data is the warning. And the pancreatitis numbers are equal to placebo in the pooled weight trials (0.2% vs 0.2%), which is why the label frames pancreatitis as something to recognize and act on rather than something the trials showed the drug clearly causes.
The label also carries a postmarketing section, where events are reported voluntarily and frequency cannot be reliably estimated. For tirzepatide it lists acute pancreatitis including hemorrhagic and necrotizing pancreatitis sometimes resulting in death; ileus, intestinal obstruction, and severe constipation including fecal impaction; anaphylaxis and angioedema; pulmonary aspiration; and acute renal failure or worsening chronic renal failure sometimes requiring hemodialysis.
Two smaller findings worth knowing: the label reports a mean heart rate increase of 1 to 3 beats per minute versus no increase on placebo, and mean increases from baseline in pancreatic amylase of 20-25% and lipase of 28-35%. The label states the clinical significance of those enzyme elevations is unknown in the absence of other signs of pancreatitis, which is a useful thing to know before an out-of-range lab result sends you into a spiral.
Why Titration Reduces GI Side Effects
The dose-escalation schedule is not a marketing artifact. The FDA label states its purpose explicitly: follow the dosage escalation "to reduce the risk of gastrointestinal adverse reactions." That sentence appears in both the Mounjaro and Zepbound labels, cross-referenced to the severe-GI warning.
The evidence sitting under it is the timing pattern in the adverse-reactions section: the majority of nausea, vomiting, and diarrhea events occurred during dose escalation and decreased over time, and most discontinuations happened in the first few months. The schedule spends four weeks at every rung so the gut adapts before the exposure rises again.
| What the FDA label specifies | Mounjaro (type 2 diabetes) | Zepbound (weight management / OSA) |
|---|---|---|
| Starting dosage | 2.5 mg subcutaneously once weekly | 2.5 mg subcutaneously once weekly for 4 weeks |
| Is the starting dose a treatment dose? | No. The label says 2.5 mg is for initiation and is not intended for glycemic control | No. The label says 2.5 mg is for initiation and is not approved as a maintenance dosage |
| First increase | To 5 mg once weekly after 4 weeks | To 5 mg once weekly after 4 weeks |
| Subsequent increases | 2.5 mg increments after at least 4 weeks on the current dose | 2.5 mg increments after at least 4 weeks on the current dose |
| Maintenance dosages | Determined by the prescriber based on glycemic control | 5, 10, or 15 mg (weight); 10 or 15 mg (OSA) |
| Maximum dosage | 15 mg weekly in adults; 10 mg weekly in patients 10 years and older | 15 mg weekly |
| If a dose is not tolerated | Prescriber decision; the label ties escalation to tolerability | The label says consider a lower maintenance dosage |
This table is educational reporting of what the FDA label specifies. It is not a plan. Your prescriber determines your dose, your escalation timing, and whether you hold or step down, based on your clinical picture. Do not start, change, stack, or convert doses on your own, and do not translate a dose from one GLP-1 medicine to another. For the full schedule read in detail, see our tirzepatide dosing guide and, for the semaglutide equivalent, the semaglutide dosing guide.
When the Label Says to Seek Medical Care
Section 17 of the label is patient counseling information: the specific things a prescriber is instructed to tell you to report. This is the most practically useful part of the entire document, and almost nobody reads it. Condensed:
- Severe or persistent gastrointestinal symptoms. Contact your provider. This is the line that separates expected nausea from a problem.
- Severe abdominal pain that may radiate to the back, with or without nausea or vomiting. The label instructs patients to discontinue promptly and contact their provider because this can indicate acute pancreatitis.
- Persistent or extended nausea, vomiting, or diarrhea. Report promptly; the label ties dehydration from these symptoms to acute kidney injury and tells patients to take precautions to avoid fluid depletion.
- Suspected gallbladder disease. Contact your provider for clinical follow-up.
- Symptoms of a hypersensitivity reaction. Stop the medicine and seek medical advice promptly.
- Symptoms of a thyroid tumor: a lump in the neck, persistent hoarseness, trouble swallowing, or shortness of breath. Report to your provider.
- Signs of low blood sugar, especially if you also take insulin or a sulfonylurea. The label tells prescribers to educate every patient on these signs.
- Any planned surgery or procedure. Tell the provider you are taking tirzepatide, because of the pulmonary aspiration reports under general anesthesia or deep sedation.
This list is a reading of the label, not triage advice
Nothing on this page can tell you whether your symptom is the expected kind or the serious kind. If something feels wrong, contact your prescriber or seek care. For a possible emergency, call 911 or go to an emergency department.
Mounjaro vs Zepbound: Same Molecule, Different Label
This confuses people constantly, so state it plainly. Mounjaro and Zepbound both contain tirzepatide. They are approved for different things.
- Mounjaro is approved for type 2 diabetes — as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years and older. It is not approved for weight loss. Prescribing Mounjaro for weight loss is off-label prescribing, a legal practice of medicine decision that a licensed clinician makes, but it is not an FDA-approved use.
- Zepbound is approved for chronic weight management in adults with obesity, or overweight with at least one weight-related condition, in combination with a reduced-calorie diet and increased physical activity, and for moderate to severe obstructive sleep apnea in adults with obesity.
- Both labels state that coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended. Stacking is a labeled negative, not a strategy.
The same drug/indication distinction applies across the class. Ozempic (semaglutide injection) and Rybelsus (oral semaglutide) are approved for type 2 diabetes; Wegovy (semaglutide injection) is approved for chronic weight management and cardiovascular risk reduction; Victoza (liraglutide) is approved for type 2 diabetes while Saxenda (liraglutide) is approved for weight management. Our GLP-1 medications list maps every approved product to its actual indication, and the GLP-1 pill guide covers the oral options. For the semaglutide brand-versus-brand version of this question, see Wegovy vs Ozempic.
Compounded Tirzepatide Has No FDA Label
Every number on this page comes from an FDA-approved label. Compounded tirzepatide does not have one. Compounded versions of tirzepatide and semaglutide are not FDA-approved, which means they have not gone through FDA review for safety, effectiveness, or quality before being marketed. The safety data above describes the branded products that were studied. It does not transfer to an unapproved copy.
The FDA has been specific about what goes wrong. The agency has stated it received multiple reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide products, where patients measured and self-administered incorrect doses or health care professionals miscalculated doses. The FDA has also said it received adverse event reports that may relate to patients prescribed compounded semaglutide or tirzepatide in doses beyond what is in the FDA-approved label — more product in a single dose, more frequent dosing, or faster titration — with some serious events, and patients seeking medical attention for nausea, vomiting, diarrhea, abdominal pain, and constipation. Separately, the FDA has warned about fraudulent compounded semaglutide and tirzepatide carrying false label information, including pharmacy names that do not exist.
The practical read
If you are prescribed a compounded product, the FDA advises talking to your provider or the compounder about how to measure and administer the intended dose, and treats deep discounts, no prescriber screening, and packaging that looks different from what you received before as red flags. Our guide to compounded semaglutide covers the legal status of compounding in more depth.
How to Bring Side Effects to Your Prescriber
Side effects are a clinical conversation, and the quality of that conversation depends on what you bring to it. A few things that make it more useful:
- Log the timing against the dose. The label's whole model is that symptoms cluster around escalation. Noting which week of which dose a symptom started tells your prescriber something a general complaint does not.
- Separate severity from presence. The label distinguishes common GI reactions from severe GI reactions, and only the second category drove most discontinuations. Describe intensity and whether you can eat and drink normally.
- List every other medication. Hypoglycemia risk changes materially if you take insulin or a sulfonylurea; the label reports 10.3% versus 2.1% on that split.
- Flag any planned procedure. The label tells you to disclose tirzepatide before general anesthesia or deep sedation.
- Ask what a dose hold looks like. The Zepbound label tells prescribers to consider a lower maintenance dosage if the current one is not tolerated. Whether that applies to you is their call.
- Ask about program monitoring. A cash-pay program that includes provider access and follow-up is structurally different from one that ships a vial. Our comparison of the best GLP-1 weight loss programs looks at what each actually includes.
Related GLP-1 guides
- Cost: verified cash-pay program pricing in our tirzepatide cost guide and semaglutide cost guide
- Lowest price: the cheapest GLP-1 without insurance, across both molecules
- Other options: Ozempic alternatives covers the non-tirzepatide routes
- Directory: browse cash-pay clinics on the weight loss and GLP-1 directory
Compare Cash-Pay GLP-1 Programs
Verified monthly prices, what each program includes, and which ones wrap real clinical monitoring around the prescription.
Browse Weight Loss ClinicsFrequently Asked Questions
What are the side effects of tirzepatide?▼
Per the FDA-approved labels, the side effects of tirzepatide are dominated by the gastrointestinal tract. The ZEPBOUND label lists the reactions reported in at least 5% of treated patients as nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation (burping), hair loss, and gastroesophageal reflux disease. The MOUNJARO label lists nausea, diarrhea, decreased appetite, vomiting, constipation, dyspepsia, and abdominal pain. Both labels also carry a boxed warning for thyroid C-cell tumors seen in rats, and warnings for pancreatitis, gallbladder disease, kidney injury from dehydration, hypoglycemia, hypersensitivity, and pulmonary aspiration under anesthesia. This is educational information, not medical advice.
What are the most common tirzepatide side effects?▼
Nausea is the most common. In the pooled ZEPBOUND weight-reduction trials, nausea was reported by 25% of patients on 5 mg, 29% on 10 mg, and 28% on 15 mg, versus 8% on placebo. Diarrhea followed at 19-23% versus 8% on placebo, then constipation at 11-17%, vomiting at 8-13%, and abdominal pain and dyspepsia around 9-10% each. In the MOUNJARO placebo-controlled diabetes trials the same reactions appear at lower rates: nausea 12-18%, diarrhea 12-17%, decreased appetite 5-11%, and vomiting 5-9%. Any gastrointestinal reaction was reported by 56% of ZEPBOUND patients versus 30% on placebo.
How long do tirzepatide side effects last?▼
The FDA label does not promise a duration, but it does describe a pattern. Both the MOUNJARO and ZEPBOUND labels state that the majority of nausea, vomiting, and diarrhea events occurred during dose escalation and decreased over time. The labels also state that most patients who stopped the drug because of adverse reactions did so during the first few months of treatment, again driven by gastrointestinal symptoms. That is the reason the label builds in a four-week step at every dose level. How long any individual person has symptoms is a question for the prescriber who is managing the titration.
Does tirzepatide cause thyroid cancer?▼
The boxed warning states that in rats, tirzepatide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures, and that it is unknown whether tirzepatide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, because the human relevance of the rodent finding has not been determined. The label does not claim the drug causes thyroid cancer in people, and it does not claim it is safe. It draws one firm line: tirzepatide is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2. The label also says routine calcitonin monitoring or thyroid ultrasound is of uncertain value for early detection.
What are the serious side effects of tirzepatide and when should I seek care?▼
The labels tell patients to contact a clinician for severe or persistent gastrointestinal symptoms; for severe abdominal pain that may radiate to the back, with or without vomiting, which can signal acute pancreatitis; for signs of gallbladder disease; for persistent nausea, vomiting, or diarrhea that could lead to dehydration and acute kidney injury; for symptoms of a hypersensitivity reaction such as swelling or trouble breathing, which the label says warrants prompt medical attention; and for symptoms of a thyroid tumor such as a lump in the neck, persistent hoarseness, trouble swallowing, or shortness of breath. The label also instructs patients to tell every provider they are taking tirzepatide before any surgery or procedure using general anesthesia or deep sedation.
Do tirzepatide side effects get worse at higher doses?▼
Partly. In the ZEPBOUND label, the rate of any gastrointestinal reaction was the same 56% at 5 mg, 10 mg, and 15 mg, but severe gastrointestinal reactions rose with dose (1.7% at 5 mg, 2.5% at 10 mg, 3.1% at 15 mg, versus 1% on placebo), as did discontinuation for gastrointestinal reasons (1.9%, 3.3%, 4.3%, versus 0.5% on placebo). MOUNJARO shows the same shape: any gastrointestinal reaction rose from 37.1% at 5 mg to 43.6% at 15 mg. The label instructs prescribers to consider a lower maintenance dosage if a patient does not tolerate the current one. Dose decisions belong to the prescriber, not to a web page.
Are compounded tirzepatide side effects the same as Mounjaro or Zepbound?▼
Compounded tirzepatide is not FDA-approved, so it has no FDA-approved label and no FDA safety, effectiveness, or quality review behind it. The FDA has said it received adverse event reports that may be related to patients prescribed compounded semaglutide or tirzepatide in doses beyond what is in the FDA-approved label, including using more product in a single dose, dosing more often, or escalating faster, with some serious events and some patients seeking medical care for nausea, vomiting, diarrhea, abdominal pain, and constipation. The FDA has also warned about fraudulent compounded semaglutide and tirzepatide carrying false label information. Treat the branded label as the reference document and ask the prescriber directly about what a compounded product contains and how to measure the dose.
Medical Disclaimer
This guide is for educational purposes only. It is not medical advice, and it is not a substitute for a consultation with a licensed clinician. Every side-effect rate, warning, contraindication, and dosing statement above is reported from the FDA-approved prescribing information for MOUNJARO (tirzepatide) and ZEPBOUND (tirzepatide) and is presented as educational reporting of what those labels specify. Clinical trial rates cannot be directly compared across drugs and may not reflect rates seen in practice. Only a licensed prescriber can determine whether tirzepatide is appropriate for you, what dose to use, and when to change or stop it. Do not start, stop, change, stack, or convert a dose based on this page. Mounjaro is approved for type 2 diabetes and is not approved for weight loss; Zepbound is approved for chronic weight management and obstructive sleep apnea. Compounded tirzepatide and semaglutide are not FDA-approved. VitalityScout is not affiliated with Eli Lilly and Company. If you experience a serious symptom, contact your clinician; in an emergency, call 911.
Sources & References
- • ZEPBOUND (tirzepatide) injection, FDA-approved prescribing information — DailyMed, label effective 2026-04-22 (boxed warning, contraindications, warnings and precautions, Table 1 adverse reactions, dose escalation)
- • MOUNJARO (tirzepatide) injection, FDA-approved prescribing information — DailyMed, label effective 2026-04-22 (indications, Table 1 adverse reactions, GI discontinuation rates, dose escalation)
- • ZEPBOUND original approval label — accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
- • MOUNJARO original approval label — accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
- • FDA — FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (compounded dosing concerns, fraudulent compounded products, telehealth red flags)
- • FDA — alerts on dosing errors associated with compounded injectable semaglutide products
- • Eli Lilly and Company — zepbound.lilly.com and mounjaro.com (official product information)